Austar Lifesciences Limited (HKG:6118)
Hong Kong · Delayed Price · Currency is HKD 0.7350
+0.0050 (0.68%)
Sep 11, 2026, 9:31 AM HKT
Austar Lifesciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,613 | 1,531 | 1,500 | 1,764 | 2,157 | 2,015 | |
Revenue Growth | 10.39% | 2.02% | -14.93% | -18.23% | 7.04% | 55.48% |
Cost of Revenue | 1,321 | 1,237 | 1,199 | 1,428 | 1,668 | 1,536 |
Gross Profit | 292.28 | 293.27 | 301.22 | 336.05 | 488.8 | 479.01 |
Selling, General & Admin | 228.18 | 224.99 | 239.08 | 300.99 | 305.93 | 298.38 |
Research & Development | 45.95 | 45.07 | 53.55 | 55.33 | 70.16 | 65.6 |
Other Operating Expenses | -17.87 | -17.17 | -25.97 | -11.15 | -6.94 | -7.63 |
Operating Expenses | 249.84 | 250.17 | 266.45 | 377.26 | 366.01 | 362.04 |
Operating Income | 42.44 | 43.1 | 34.77 | -41.21 | 122.79 | 116.97 |
Interest Expense | -10.05 | -11.95 | -17.01 | -13.96 | -9.59 | -4.4 |
Interest & Investment Income | 1.17 | 1.46 | 2.9 | 3.29 | 2.27 | 1.47 |
Earnings From Equity Investments | 5.87 | 4.63 | 0.3 | 6.73 | 9.54 | 10.66 |
Currency Exchange Gain (Loss) | -3.42 | 8.74 | -4.1 | 6.83 | -5.17 | -3.74 |
Other Non Operating Income (Expenses) | -0.16 | -0.16 | -0.19 | -0.19 | - | - |
EBT Excluding Unusual Items | 35.86 | 45.81 | 16.67 | -38.51 | 119.83 | 120.95 |
Gain (Loss) on Sale of Investments | - | - | -0.42 | - | - | 198.99 |
Gain (Loss) on Sale of Assets | -0.09 | -0.47 | -0.2 | 4.1 | -0.3 | -0.72 |
Other Unusual Items | -0.28 | 2.79 | 5.13 | - | - | - |
Pretax Income | 35.49 | 48.13 | 21.17 | -34.41 | 119.53 | 319.23 |
Income Tax Expense | 17.36 | 15.25 | 7.6 | 0.38 | 18.89 | 46.6 |
Earnings From Continuing Operations | 18.12 | 32.88 | 13.57 | -34.79 | 100.64 | 272.62 |
Earnings From Discontinued Operations | - | - | - | -80.87 | -16.78 | - |
Net Income to Company | 18.12 | 32.88 | 13.57 | -115.66 | 83.86 | 272.62 |
Minority Interest in Earnings | -0.86 | 0.93 | 2.51 | 2.18 | 3.6 | 4.68 |
Net Income | 17.27 | 33.81 | 16.08 | -113.47 | 87.46 | 277.3 |
Net Income to Common | 17.27 | 33.81 | 16.08 | -113.47 | 87.46 | 277.3 |
Net Income Growth | -50.94% | 110.24% | - | - | -68.46% | 737.76% |
Shares Outstanding (Basic) | 513 | 513 | 513 | 513 | 513 | 513 |
Shares Outstanding (Diluted) | 513 | 513 | 513 | 513 | 513 | 513 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 0.03 | 0.07 | 0.03 | -0.22 | 0.17 | 0.54 |
EPS (Diluted) | 0.03 | 0.07 | 0.03 | -0.22 | 0.17 | 0.54 |
EPS Growth | -50.94% | 110.25% | - | - | -68.40% | 800.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 136.54 | 109 | 78.31 | -131.88 | -155.04 | -204.02 |
Free Cash Flow Per Share | 0.27 | 0.21 | 0.15 | -0.26 | -0.30 | -0.40 |
Gross Margin | 18.12% | 19.16% | 20.08% | 19.05% | 22.66% | 23.77% |
Operating Margin | 2.63% | 2.82% | 2.32% | -2.34% | 5.69% | 5.80% |
Profit Margin | 1.07% | 2.21% | 1.07% | -6.43% | 4.06% | 13.76% |
Free Cash Flow Margin | 8.46% | 7.12% | 5.22% | -7.48% | -7.19% | -10.13% |
EBITDA | 81.81 | 73.05 | 65.07 | -19.82 | 137.06 | 130.62 |
EBITDA Margin | 5.07% | 4.77% | 4.34% | -1.12% | 6.35% | 6.48% |
D&A For EBITDA | 39.37 | 29.95 | 30.29 | 21.4 | 14.27 | 13.65 |
EBIT | 42.44 | 43.1 | 34.77 | -41.21 | 122.79 | 116.97 |
EBIT Margin | 2.63% | 2.82% | 2.32% | -2.34% | 5.69% | 5.80% |
Effective Tax Rate | 48.93% | 31.68% | 35.90% | - | 15.81% | 14.60% |
Advertising Expenses | - | 7.83 | 6.55 | 8.6 | 5.83 | 12.76 |